Every Form 4 that Beta Bionics, Inc. (BBNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BBNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBNX filings page.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 370 shares of common stock on October 1, 2026, at a weighted average sale price of $18.96 per share under a Rule 10b5-1 plan adopted on June 10, 2026. Prices ranged from $18.96 to $19.9599 per share. After the sale, he held 56,109 shares directly.
Beta Bionics, Inc. (BBNX) director Christy Jones reported selling 6,430 shares of common stock on September 22, 2026, at $23 per share. The transaction is described as a sale in the open market or a private transaction and was made pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. Jones reported holding 19,564 shares directly after the sale.
Beta Bionics, Inc. (BBNX) reports that Chief Commercial Officer Mark Hopman sold 35,994 shares of common stock on September 9, 2026 at $18.4628 per share in a sale described as open market or private. The sale was made pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
After this transaction, Hopman beneficially owned 88,033 shares of Beta Bionics common stock. This Form 4 amendment corrects an earlier filing that had incorrectly reported the number of shares disposed and the resulting beneficial ownership.
Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 30,779 shares of common stock on September 16, 2026. The sale was executed at a weighted average price of $20.1319 per share, in transactions ranging from $20.00 to $20.64, under a Rule 10b5-1 Plan adopted on June 10, 2026. After these sales, Hopman directly holds 56,479 shares of Beta Bionics common stock.
Beta Bionics, Inc. (BBNX) reported that Chief Product Officer Mike Mensinger sold 2,650 shares of common stock on September 16, 2026 at $22.00 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on September 8, 2025, and he continued to hold 177,390 shares of common stock directly after the transaction.
Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 775 shares of common stock on September 14, 2026 at a price of $15.52 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2026, and Hopman now holds 86,382 shares directly.
Beta Bionics, Inc. (BBNX) disclosed that Chief Commercial Officer Mark Hopman sold 36,870 shares of common stock on September 9, 2026 in an open market or private transaction at an average price of $18.4628 per share. The transaction was executed pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026, and Hopman now directly holds 87,157 shares of Beta Bionics common stock.
Beta Bionics, Inc. (BBNX) reported that President & CEO Sean Saint sold 5,641 shares of common stock on September 3, 2026 at a weighted average price of $20.0778 per share, in an open-market transaction executed pursuant to a Rule 10b5-1 Plan adopted on September 5, 2025.
After this planned sale, he continued to hold 398,429 shares of Beta Bionics common stock directly.
Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 5,327 shares of common stock on September 2, 2026. The sale was made to cover tax withholding obligations arising from the vesting of restricted stock units. The weighted average sale price was $19.1131 per share, within a range of $18.89 to $19.545. After this sale, Hopman continued to hold 124,027 shares of Beta Bionics common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Beta Bionics, Inc. (BBNX) reported that Chief Medical Officer Steven Jon Russell sold 4,221 shares of common stock on September 2, 2026. The filing states these shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, and not as a discretionary sale of investment holdings.
The weighted average sale price was $19.1131 per share, within a reported range of $18.89 to $19.545. After this transaction, Russell held 169,628 shares of Beta Bionics common stock directly. No transactions were reported under a Rule 10b5-1 trading plan.
Beta Bionics, Inc. (BBNX) reported that Chief Product Officer Mike Mensinger sold 4,375 shares of common stock on September 2, 2026, in an open-market or private transaction. According to the company’s disclosure, these shares were sold to cover tax withholding obligations related to vesting restricted stock units, and Mensinger held 180,040 shares directly after the sale.
Beta Bionics, Inc. (BBNX) reported that Chief Financial Officer Stephen Feider sold 6,675 shares of common stock on September 2, 2026 at a weighted average price of $19.1131 per share, with prices ranging from $18.89 to $19.545, to cover tax withholding obligations from vesting restricted stock units, and now holds 159,378 shares directly. No Rule 10b5-1 trading plan is reported.
Beta Bionics, Inc. (BBNX) reported that President & CEO Sean Saint sold 16,867 shares of common stock on September 2, 2026 at a weighted average price of $19.1131 per share. According to the disclosure, the shares were sold to cover tax withholding obligations from vesting restricted stock units, and Saint held 404,070 shares directly after the transaction.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an amended insider transaction combining option exercises and share sales. On June 26 and June 29, 2026, he exercised options for a total of 10,000 shares of common stock at a conversion price of $5.10 per share and sold 10,000 shares in open-market transactions.
The weighted average sale prices were $17.046782 on June 26 and $17.0304 on June 29, with trades executed between $17.00 and about $17.12. Following these transactions, he held 166,053 shares of common stock directly. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. This amendment corrects the number of shares subject to the June 26, 2026 option exercise and the number of securities beneficially owned after the transactions.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell pattern in Common Stock. He exercised stock options covering 9,878 shares at an exercise price of $5.10 per share and sold 10,000 shares in open-market transactions at weighted average prices around $17.04 on June 26, 2026 and June 29, 2026. The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. Following these transactions, he directly holds 165,931 shares of Common Stock, indicating he retained a large majority of his equity position.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of common stock. On June 24, 2026, he sold 1,258 shares at a weighted average price of $15.0083 per share, under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025. Following this sale, he directly holds 129,354 shares of common stock.
Beta Bionics, Inc. director Christy Jones reported an open-market sale of 1,406 shares of Common Stock at $15.00 per share. After the transaction, she directly holds 25,994 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating it was scheduled in advance.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of 275 shares of Common Stock at $12.31 per share. After this transaction, he directly holds 130,612 shares. The sale was executed under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025, indicating it was scheduled in advance.
Beta Bionics, Inc. director Christy Jones reported an open-market sale of 2,811 shares of Common Stock at $14.00 per share. The transaction was executed on June 4, 2026 pursuant to a pre-arranged Rule 10b5-1 Plan adopted on February 19, 2026. After this sale, Jones directly holds 27,400 shares, indicating she retains a substantial ongoing equity position in the company.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a small share sale primarily for tax purposes. He sold 4,378 shares of Common Stock on June 2, 2026 at a weighted average price of $12.6071 per share, within a price range of $12.30 to $12.93.
According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units rather than a discretionary portfolio decision. After this transaction, Mensinger still directly owns 184,415 shares of Beta Bionics common stock.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of 5,329 shares of Common Stock. The shares were sold at a weighted average price of $12.6071 per share to cover tax withholding obligations tied to the vesting of restricted stock units, according to the footnotes. After this transaction, Hopman directly holds 130,887 shares of Beta Bionics common stock, indicating that the sale represents a relatively small portion of his overall position and is primarily a tax-related event rather than a discretionary reduction in ownership.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported an open-market sale of 4,222 shares of common stock on June 2, 2026. The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
The weighted average sale price was $12.6071 per share, with individual trade prices ranging from $12.30 to $12.93. After these transactions, he directly holds 173,849 shares of Beta Bionics common stock, indicating this was a relatively small, tax-driven sale.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an open-market sale of 6,676 shares of common stock. The shares were sold on June 2, 2026 primarily to cover tax withholding obligations tied to vesting restricted stock units. The weighted average sale price was $12.6071 per share, with trade prices ranging from $12.30 to $12.93. Following this tax-related sale, Feider directly holds 166,053 shares of Beta Bionics common stock.
Beta Bionics, Inc. President & CEO Sean Saint reported an open-market sale of 16,872 shares of common stock at a weighted average price of $12.6071 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 420,937 shares directly.
MICHEL GERARD J reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director MICHEL GERARD J received an equity grant of 16,965 shares of Common Stock on May 21, 2026. The award is structured as a restricted stock unit grant under the company’s 2025 Equity Incentive Plan and was issued at no cash cost, raising his direct holdings to 33,509 shares.
Beta Bionics, Inc. director Christy Jones reported both a stock award and a small share sale. On May 21, 2026, Jones received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, at no cash cost.
On the same date, Jones sold 1,998 common shares at $9.95 per share in an open‑market transaction. According to the filing, this sale was made pursuant to a Rule 10b5‑1 trading plan adopted on February 19, 2026, and Jones held 13,246 common shares directly after the sale.
Palasis Maria reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Maria Palasis received an equity award of 16,965 shares of Common Stock on May 21, 2026. The grant was issued at no cash cost as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, bringing her direct holdings to 29,397 shares.
Dearen Danny L. reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Danny L. Dearen reported receiving an equity grant in the form of restricted stock units. On May 21, 2026, he was awarded 16,965 shares of common stock at a stated price of $0.00 per share under the company’s 2025 Equity Incentive Plan. After this award, his direct holdings increased to 32,209 shares of common stock. This is a compensation-related grant rather than an open-market purchase or sale.
CARNEY SEAN reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Sean Carney received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The award was recorded at a price of $0.00 per share, bringing his direct holdings to 32,209 shares after the grant.
Beta Bionics, Inc. director Adam Lezack reported a mix of stock awards and small planned sales. On May 21, 2026, he received a grant of 16,965 shares of Common Stock at no cost, described as a restricted stock unit award under the company’s 2025 Equity Incentive Plan.
That same day he executed an open-market sale of 1,000 shares at $9.95 per share, followed by a sale of 998 shares at $11.21 per share on May 22, 2026. The filing shows he held 27,399 shares directly after the most recent sale. Both sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
Beta Bionics Chief Commercial Officer Mark Hopman sold 2,917 shares of Common Stock in open-market transactions, primarily to cover tax withholding tied to vested restricted stock units. The sales occurred at weighted average prices around $30–31 per share under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Hopman directly holds 136,216 shares of Beta Bionics Common Stock, indicating he retains a substantial equity stake in the company.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported an open-market sale of 1,025 shares of Common Stock at an average price of $29.3359 per share on December 2, 2025. According to the footnote, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 178,071 shares directly.
Beta Bionics, Inc. reported that Chief Product Officer Mike Mensinger received a grant of employee stock options covering 91,520 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036. According to the disclosure, these options vest in 36 equal monthly installments starting on March 1, 2026, meaning the award vests gradually over three years as continued service is provided.
Beta Bionics, Inc. reported that its Chief Medical Officer, Russell Steven Jon, received a grant of stock options. The award covers 91,520 options to purchase common stock at an exercise price of $12.63 per share, expiring on February 26, 2036.
The options were granted at no cost and represent a compensation-related award rather than an open-market purchase. According to the vesting terms, the options will vest in 36 equal monthly installments starting on March 1, 2026, meaning the officer earns the right to exercise them gradually over three years.
Beta Bionics, Inc. reported that President & CEO Sean Saint received a grant of employee stock options on Common Stock. The award covers 287,944 options with an exercise price of $12.63 per share and an expiration date of February 26, 2036.
The options were granted at no cost and are classified as a compensation-related acquisition rather than an open-market purchase. According to the vesting terms, the underlying shares will vest in 36 equal monthly installments starting on March 1, 2026, aligning the CEO’s incentives with longer-term company performance.
Beta Bionics, Inc. reported that Chief Commercial Officer Mark Hopman received an employee stock option grant covering 91,520 shares of common stock. The option has an exercise price of $12.63 per share and expires on February 26, 2036.
The award was granted at no cost on the grant date and vests in 36 equal monthly installments starting on March 1, 2026, reflecting a long-term equity compensation arrangement rather than an open-market share purchase or sale.
Beta Bionics, Inc. reported that Chief Financial Officer Stephen Feider received a grant of employee stock options covering 110,342 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036.
The grant was awarded as compensation and did not involve any open-market buying or selling. According to the terms, the options vest in 36 equal monthly installments starting on March 1, 2026, meaning the CFO earns the right to exercise them gradually over three years.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 353 shares of common stock in an open-market transaction on March 4, 2026. The shares were sold at an average price of $11.57 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 13, 2025.
After this sale, Hopman directly owned 139,133 shares of Beta Bionics common stock. The filing characterizes the transaction as an open-market sale, and the trading plan structure indicates it was executed under a pre-established schedule rather than at the insider’s discretion on the trade date.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported new equity awards and a small share sale. He received a grant of 109,105 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan and 58,749 stock options, which vest in 36 equal monthly installments starting on March 1, 2026.
On March 2, 2026, he sold 834 shares of common stock in an open-market transaction at a weighted average price of $12.3616, in a price range between $12.20 and $12.55, to cover tax withholding obligations tied to restricted stock unit vesting. After this sale, he directly owned 139,486 shares of common stock.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported multiple equity transactions. He sold 1,026 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share, with prices ranging from $12.20 to $12.55, to cover tax withholding obligations from vesting restricted stock units.
He also acquired 109,105 shares of common stock as a grant classified as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. In addition, he received an employee stock option covering 58,749 shares, which is scheduled to vest in 36 equal monthly installments starting from March 1, 2026.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a mix of equity grants and a small share sale. On February 27, 2026, he received a grant of 58,749 employee stock options and 109,105 shares of common stock at a price of $0.0000 per share, including a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The option award will vest in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,064 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share to cover tax withholding obligations associated with restricted stock unit vesting, leaving him with 188,793 common shares directly held after that sale.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported both stock awards and a small share sale. On February 27, 2026, he received 131,543 shares of common stock as restricted stock units and an option for 70,831 shares that vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,428 shares of common stock at a weighted average price of $12.3616 to cover tax withholding obligations related to restricted stock unit vesting, and held 172,729 common shares directly afterward.
Beta Bionics, Inc. President & CEO Sean Saint reported a mix of equity awards and a small tax-related share sale. On February 27, 2026, he acquired 343,269 shares of common stock as a restricted stock unit award under the 2025 Equity Incentive Plan and received an employee stock option for 184,837 shares, which vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 3,384 shares of common stock in an open-market transaction at a weighted average price of $12.3616, solely to cover tax withholding obligations from restricted stock unit vesting, and held 437,809 common shares directly afterward.
Beta Bionics, Inc. director Michel Gerard reported receiving an award of 3,997 shares of common stock on 01/13/2026. The filing shows this as an automatic acquisition at a price of $0 per share, representing a restricted stock unit grant under the company’s 2025 Equity Incentive Plan. Following this award, Gerard beneficially owns 16,544 shares of Beta Bionics common stock in direct form.
Beta Bionics, Inc. director Sean Carney reported a stock-based award. On 01/13/2026, he acquired 3,997 shares of common stock at a price of $0, described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. After this grant, he beneficially owned 15,244 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. director Maria Palasis reported receiving a grant of 3,997 shares of common stock on January 13, 2026. The transaction is coded as an acquisition at a price of $0 per share and is described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this award, Palasis beneficially owns 12,432 shares of Beta Bionics common stock, held in direct ownership.
Beta Bionics, Inc. director Christy Jones reported an equity award on a Form 4. On January 13, 2026, Jones acquired 3,997 shares of common stock with a transaction code "A," indicating an award rather than an open-market purchase, at a stated price of $0 per share.
The footnote explains this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Jones beneficially owns 15,244 shares of Beta Bionics common stock in direct ownership.
Beta Bionics, Inc. director Adam Lezack reported an equity award of 3,997 shares of common stock. The Form 4 shows that on January 13, 2026, he acquired 3,997 shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. A footnote explains that this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Lezack beneficially owns 12,432 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. director Danny L. Dearen reported an equity award of 3,997 shares of common stock. The Form 4 shows the shares were acquired on January 13, 2026 with a transaction code "A", indicating an award or grant rather than an open‑market purchase.
According to the footnote, the grant represents a restricted stock unit award issued under the company’s 2025 Equity Incentive Plan at a stated price of $0 per share, which is typical for RSU grants. After this transaction, Dearen beneficially owns 15,244 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a planned sale of company stock. On January 6, 2026, he sold 2,200 shares of common stock at a weighted average price of $30.1005 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owned 80,752 shares of Beta Bionics common stock directly. The filing notes that individual sale prices ranged between $30.00 and $30.13, and detailed breakdowns are available to regulators, the company, or its security holders on request.